DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...

The best-selling author and podcaster on how to preserve robust physical, cognitive and emotional health, and how Medicine ...

This ischemic benefit of sotagliflozin on both MI and stroke has not been observed in trials of selective SGLT2 inhibitors ... SGLT1 inhibition as a potential mechanism for the ischemic benefit ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

although with different mechanisms of action there is potential for combination use. With two large-scale trials showing a mortality benefit in hand, it looks assured that SGLT2 inhibitors will ...

At the foundation of healthspan medicine are the pillars of health. These are easily understood through four simple verbs: ...

The compound "provides a unique dual mechanism of action (adenosine monophosphate ... antihyperglycemic medications," including SGLT2 inhibitors and DPP-4 inhibitors. For certain patients ...

as it has not been observed in trials of selective SGLT2 inhibitors." "These results demonstrate a new mechanism of action -- combined blockade with sotagliflozin of the SGLT1 receptors found in ...

Several mechanisms may be involved in this potential ... who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December ...

These SGLT 2 inhibitors prevent glucose absorption in ... “For some unknown reason the drug also protects the kidney. The drug’s mechanism reduces protein leak into urine.